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Abstract: The development of immunosuppressive drugs has in recent years been focused 
on prevention of acute rejection. This has led to an increase in one-year allograft survival. 
However, these drugs have non-immune effects which contribute to the high incidence of late 
graft loss, as a consequence of chronic allograft nephropathy, and the death of patients. As an 
immune-speciﬁ  c alternative to conventional immunosuppressants, new biotechnology tools have 
been developed; they target the costimulation signal of T-cell activation, particularly by the 
“classical” B7/CD28 and CD40/CD40L pathways. Here, we review the limitations of current 
immunosuppressive protocols, the beneﬁ  ts of classical B7/CD28 costimulation blockade, and 
the ﬁ  rst large-scale clinical application of this strategy to human transplantation with belatacept. 
We will also consider novel costimulatory molecules of the B7/CD28 and TNF/TNF-R families, 
which appear to be important for the functions of memory and effector T-cells.
Keywords: kidney transplantation, immunosuppressants, costimulation, belatacept, chronic 
allograft nephropathy, fusion protein
New immunosuppressive drugs have greatly decreased the frequency of graft failure 
due to acute rejection, but have had little effect on the incidence of late graft loss due 
to chronic allograft nephropathy or on patient deaths (Meier-Kriesche et al 2004). 
This is largely due to the broad non immune effects of current immunosuppressive 
drugs, the targets of which are ubiquitous and non speciﬁ  c. Progress has recently 
been made in dissecting the T-cell/antigen presenting cell (APC) interactions and, in 
particular, the costimulation pathways critical for T-cell activation. Biotechnology 
has developed new tools – monoclonal antibodies and fusion proteins – targeting 
the relevant molecules very precisely.
Here we review the limitations of current immunosuppressive protocols, the 
beneﬁ  ts of classical B7/CD28 costimulation blockade, and its ﬁ  rst large-scale appli-
cation with belatacept. We will also address novel costimulatory molecules of the 
B7/CD28 and TNF/TNF-R families, which appear to be particularly important for the 
functions of memory and effector T-cells. These categories of T-cells play important 
roles in allograft rejection and are less susceptible to classical costimulation blockade 
(London et al 2000).
Limitations of current immunosuppressive 
protocols
Because there is a relationship between acute rejection and late allograft failure, the 
recent development of immunosuppressive drugs has been focused on the prevention of 
acute rejection. Thus, with the introduction of cyclosporine in the early 1980s and newer 
immunosuppressive drugs in the 1990s (tacrolimus, mycophenolate mofetil or MMF Biologics: Targets & Therapy 2007:1(3) 204
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and sirolimus), the incidence of acute rejection has substantially 
decreased to 10 to 30% (Denton et al 1999). Consequently, 
one-year allograft survival has increased: according to the 
OPTN/SRTR report, the adjusted one-year graft survival for 
recipients of deceased non-extended criteria donor kidneys was 
91% (Cohen et al 2006). However, contrary to the optimistic 
projections for the 1988–1995 period (Hariharan et al 2000), 
actuarial analysis has revealed only a small increase in graft 
half-lives: from 6 years in 1988 to 8 years in 1995 (Meier-Kri-
esche et al 2004). Chronic allograft nephropathy (CAN) and 
death of transplant patients with a functioning graft are the main 
causes of late allograft failure. The broad non immune effects 
of current immunosuppressive drugs (see Table 1) contribute 
to both CAN and the risk of patient death.
Death of patients with functioning graft
Death with a functioning graft accounts for 50% of late allograft 
failure (Pascual et al 2002), and 43% of such cases are due to 
cardiovascular events (West et al 1996). The following factors 
are frequently encountered in renal transplant patients and 
contribute to cardiovascular diseases: older age, obesity, hyper-
tension, diabetes mellitus, hyperlipidemia, smoking, long-term 
chronic renal failure and dialysis. Patients may present these 
factors before transplantation, but some are frequent side 
effects of currently used immunosuppressive drugs (Table 1). 
Other causes of death include infection and cancer, often 
associated with a generally high immunosuppressive burden 
rather than the direct effect of a single molecule. An exception 
is the lower incidence of cancers observed in patients treated 
with mTOR inhibitors – sirolimus and everolimus – because of 
their anti-proliferative effect on several types of malignancies 
(Kauffman et al 2005).
Chronic allograft nephropathy
CAN is a pathological ﬁ  nding on kidney biopsy; it consists of 
ﬁ  brosis and tubular atrophy, and the clinical presentation is 
often a gradual decrease in GFR associated with proteinuria and 
hypertension (Pascual et al 2002). CAN is not a single patho-
genic entity but most frequently the result of combined immu-
nological and nonimmunological manifestations (Table 2).
The immunological factors include episodes of acute 
cellular rejection and also sub-clinical acute rejections 
deﬁ  ned as histological evidence of acute cellular rejection 
from routine kidney biopsies (those performed not because 
of a deterioration of renal function). The recent histological 
characterization of antibody-mediated rejection (AMR) with 
C4d staining and the detection of donor-speciﬁ  c antibodies 
(DSA) with sensitive techniques have indicated the role of 
humoral immunity in acute and chronic rejection (Snanoudj 
et al 2005). Circulating DSA are present in many (100% in 
some series) patients with histological evidence of chronic 
rejection and in 50% of cases, these antibodies appear 
de novo after transplantation (Lee et al 2002). Moreover, 
among patients with de novo DSA, the rate of graft failure 
after one year is 8.6%, whereas it is only 3.0% for patients 
without these antibodies (Terasaki and Ozawa 2004).
The non immunological features include classic conditions 
that increase the rate of decline of renal function in all nephropa-
thies (diabetes, hypertension, hyperlipidemia, obesity). The 
“quality” of the donor is becoming a critical issue. Indeed, 
because of the shortage of organs and the growing demand, 
kidneys are currently procured from elderly deceased donors, 
donors with pre-existing hypertension, diabetes, cardio-vascu-
lar risk factors or disease, and mild renal failure. These grafts 
are called “extended-criteria donor (ECD) kidneys” (Rosengard 
et al 2002). The clinical outcome with these kidneys is better 
than that with dialysis, but some studies have shown a higher 
risk of late allograft failure compared with allografts procured 
from non-marginal donors. For the same reasons, kidneys 
harvested from non heart-beating donors are being transplanted 
more frequently than in the past, despite the risk of delayed graft 
Table 1 Main non-immune side effects of immunosuppressive 
maintenance drugs used in kidney transplantation
Drugs Side  effects
Steroids Diabetes,
 Hypertension,
 Hyperlipidemia,
 Obesity
Calcineurin Inhibitors  Hypertension1,
(Cyclosporine, Tacrolimus)  Hyperlipidemia1,
 Diabetes2,
 Nephrotoxicity,
  BK virus nephropathy2
Anti-proliferative Drugs  Hematological (Neutropenia,
(Azathioprine, Anemia)
Mycophenolate Mofetil,  Diarrhea3,
Sodium Mycophenolate)  BK virus nephropathy3
mTOR4 inhibitors  Delayed wound healing,
(Sirolimus, Everolimus)  Hyperlipidemia,
 Hematological  disorders
 (Anemia,  Thrombopenia,
 Leucopenia),
 Pneumopathy  (sirolimus),
  Increase of CNI nephrotoxicity
1More frequent with cyclosporine.
2More frequent with tacrolimus.
3More frequent with prodrugs of mycophenolic acid.
4Mammalian.
Abbreviations: TOR, Target of Rapamycin.Biologics: Targets & Therapy 2007:1(3) 205
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dysfunction being greater. Both types of kidneys are particularly 
sensitive to other sources of injury, and particularly to the 
nephrotoxic effects of calcineurin inhibitors (CNI).
The benefits afforded by CNI in terms of short-term 
survival, makes their detrimental effects on long-term survival 
difﬁ  cult to study. Nankivell et al performed repeated biopsy 
protocols over 10 years with 120 kidney-pancreas transplant 
patients receiving cyclosporine or tacrolimus. They showed that 
histological lesions associated with CNI nephrotoxicity (arterio-
lar hyalinosis with vascular narrowing, stripped-band ﬁ  brosis) 
increase with time after transplantation and become universal by 
ten years; these lesions constitute the chief cause of late injury 
and decline in renal function (Nankivell et al 2003).
Because of the long-term nephrotoxicity of CNI, their 
metabolic side-effects and the resulting risk of CAN and 
death of patients, recent immunosuppressive protocols tend 
to minimize or even avoid the use of CNI. It is now clear that 
complete withdrawal of CNI from the gold standard triple 
therapy (with steroids and MMF) results in a signiﬁ  cant 
increase in the rate of late acute rejection. Nevertheless, it 
seems reasonable, with MMF as anti-proliferative drug, to 
use lower doses of CNI than previously with azathioprine 
(Ekberg et al 2007). However, how much long-term toxicity 
can be reduced by this approach remains to be determined 
(Kaplan and Budde 2007). An attractive alternative to CNI 
is costimulation blockade and the possibility for precise T-
cell targeting, which could protect patients from many of the 
side-effects common with classical immunosuppressants.
Immunological basis of the 
co-stimulation blockade
T-cell activation by three signals
During the alloimmune response, both naïve and memory 
alloreactive T-cells are engaged by dendritic cells (DCs) of 
both donor and recipient origin (von Andrian and Mackay 
2000). T lymphocyte activation requires three signals 
(Figure 1). The ﬁ  rst involves T-cell receptor triggering by 
donor antigen on the surface of DCs or other APCs (Bromley 
et al 2001). The second signal or “costimulation signal” is not 
antigen-speciﬁ  c. Many pairs of molecules on the surface of 
T-lymphocytes and APCs can contribute to the costimulation 
signal (Table 3). However, the B7/CD28 and CD40/CD40L 
pathways are probably the most important and best char-
acterized in T-cell activation. The costimulation signal is 
delivered when B7-1/CD80 and B7-2/CD86 on the surface 
of DCs engage CD28 on T-cells (Bromley et al 2001). These 
two signals activate three transduction pathways (Halloran 
2004) that result in the production of numerous factors, 
including interleukin-2 (IL-2) and the α-chain of its receptor, 
CD25, and the CD40 Ligand. CD40 is expressed on all APCs 
(including B cells) and its ligand (CD40L or CD154) is on 
activated CD4+ T-cells and on a subset of CD8+ T-cells and 
NK cells. CD40 stimulation triggers important signals for 
antibody production by B cells and strongly induces B7 and 
MHC expression on APCs. The CD40/CD40L system thus 
ampliﬁ  es antigen presentation and the ﬁ  rst antigen-speciﬁ  c 
signal (van Kooten and Banchereau 1997).
IL-2 binding to its receptor activates the mTOR (“target 
of rapamycin”) pathway – the third signal – resulting in 
T-cell clonal proliferation and in the generation of effector 
T-cells (Halloran 2004).
The B7/CD28/CTLA-4 pathway
This pathway is characterized by the dual speciﬁ  city of two 
B7 family members, B7-1 and B7-2, for both the stimulatory 
receptor CD28 and the inhibitory receptor CTLA-4 (cyto-
toxic T-lymphocyte-associated antigen 4/CD152). CD28 
provides a T-cell activation signal, and CTLA-4 inhibits 
Table 2 Factors involved in the pathogenesis of chronic allograft nephropathy
Immunological factors  Non-immunological factors
Episodes of Acute Rejection  Extended-Criteria Donors
Sub-clinical Acute rejection  Ischemia-reperfusion Injury
Chronic alloimmune response  Delayed Graft Function
  Hypertension
  Hyperlipidemia
Risk factors  Diabetes
HLA sensitization (pregnancy, previous  Infections (Bacterial Pyelonephritis/
transplantation, blood transfusion), DSA  Polyomavirus Nephropathy)
Poor HLA Matching  CNI nephrotoxicity
Delayed Graft Function  Surgical complications (Arterial and Urinary
Chronic suboptimal immunosuppression  Stenosis)
Non-compliance of patients  Recurrent or De Novo Nephropathy
Abbreviations: DSA, Donor-Speciﬁ  c Antibodies; CNI, Calcineurin inhibitors.Biologics: Targets & Therapy 2007:1(3) 206
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T-cell responses (Table 3) (Greenwald et al 2005). CD28 
is constitutively expressed on T-cells, whereas CTLA-4 
expression is rapidly upregulated following T-cell activa-
tion. CTLA-4 has a higher receptor afﬁ  nity for both B7-1 
and B7-2 than CD28.
Recently, a new regulatory mechanism was demonstrated 
for DCs, through B7/CTLA-4 reverse signaling (meaning 
from T-cell to DC) (Finger and Bluestone 2002; Grohmann 
et al 2002). CTLA-4, when binding to B7, may activate the 
immunosuppressive pathway of tryptophan catabolism in DCs 
(Grohmann et al 2002). This pathway consists of the produc-
tion by DCs of Interferon-γ, which stimulates the indoleamine 
2,3-dioxygenase (IDO) to degrade tryptophan. The resulting 
degradation products and tryptophan deprivation inhibit T-
cells proliferation and promote their apoptosis. These two-way 
B7/CTLA-4 interactions may be involved in the inhibition of 
T-cell responses. Work with a model of murine islet allografts 
shows that the long-term survival induced by CTLA4-Ig – a 
fusion protein of CTLA-4 with an immunoglobulin – depends 
on effective tryptophan catabolism and that this effect disap-
pears in the presence of 1-methyltryptophan, a pharmacologi-
cal inhibitor of IDO (Grohmann et al 2002). However, Pree 
et al found divergent results regarding the role of IDO in vivo 
(Pree et al 2007). They tested costimulation blockade as a 
component of murine bone marrow transplantation protocol 
for the induction of mixed chimerism and donor-speciﬁ  c 
skin graft tolerance. They demonstrated that induction of 
high-level chimerism and permanent skin engraftment 
obtained with CTLA4-Ig occurred independently of IDO. 
Indeed, chimerism and graft survival were not affected by 
implantation of pellets releasing 1-methyltryptophan. The use 
in this study of the human construct of CTLA4-Ig abatacept, 
which may have different binding properties than the murine 
fusion protein, may explain this divergence.
B7/CTLA-4 interactions and regulatory 
T-cells
A subgroup of CD4+CD25+ T-lymphocytes, termed regula-
tory or suppressor T-lymphocytes (T-reg), are central to the 
establishment of transplantation tolerance in several experi-
mental models (Graca et al 2002). Their clinical signiﬁ  cance 
in human transplantation is currently being investigated. 
Muthukumar et al (2005) found that urinary levels of FOXP3 
mRNA, a functional factor speciﬁ  c to T-regs, were inversely 
correlated with serum creatinine at the time of acute rejection. 
Moreover, levels of FOXP3 mRNA were signiﬁ  cantly higher 
in the group with successful reversal of acute rejection than 
in the group without reversal. The patients in higher third 
of FOXP3 mRNA level had the lowest rate of graft failure 
Figure 1 T-cell activation by three signals. The ﬁ  rst involves T-cell receptor (TCR) triggering by donor antigen on APCs (antigen presenting cells). The second signal 
or “costimulation signal” is delivered when B7-1/CD80 and B7-2/CD86 on the surface of APCs engage CD28 on T-cells. These two signals activate three transduction 
pathways (the Nuclear Factor-κB or Nf-κB pathway, the mitogen-activated protein (MAP) kinase pathway and the calcium-calcineurin pathway) that result in the produc-
tion of numerous factors, including interleukin-2 (IL-2), the α–chain of its receptor, CD25, and the CD40 Ligand. CD40 is expressed on all APCs (including B cells) and its 
ligand (CD40L or CD154) is on activated CD4+ T-cells and on a subset of CD8+ T-cells and NK cells. Stimulation of CD40 on APC by CD40L triggers important signals for 
antibody production by B cells and strongly induces B7 and Major Histocompatibility Complex (MHC) expression on APCs. IL-2 binding to its receptor activates the mTOR 
(“target of rapamycin”) pathway – the third signal – resulting in T-cell clonal proliferation.
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following an acute rejection episode. In sum, this study 
suggests that FOXP3-expressing T-regs play a role in the 
limitation of alloimmune response and that the lack of sup-
pression exerted by these cells during an episode of acute 
allograft rejection increases the risk of incomplete resolution 
and graft loss. (Muthukumar et al 2005). Moreover, this 
ﬁ  nding has potential for the identiﬁ  cation of patients at risk 
of graft failure after an episode of rejection.
The lack of expression of B7-1 and B7-2 on the surface 
of effector cells results in lower susceptibility to suppres-
sion exerted by CD4+CD25+ T-cells. Indeed, direct contact 
between suppressor and effector cells is required in vitro, 
through the binding of CTLA-4 on T-reg and B7-1/B7-2 on 
effector cells. (von Boehmer 2005). In vivo suppression also 
requires B7 expression on effector cells. In a skin transplant 
model, blockade of the CTLA-4 pathway abolishes immuno-
regulation by CD4+CD25+ T-cells, suggesting that CTLA-4 
is required for tolerance (Kingsley et al 2002).
Experimental models of “classical” 
costimulation blockade
The B7/CD28 pathway
One of the ﬁ  rst tools used to target the B7/CD28 pathway was 
the CTLA4-Ig molecule, a fusion protein consisting of the 
extracellular domain of CTLA-4 and the Fc domain of IgG. 
CTLA4-Ig may act by directly disrupting B7/CD28 cross-
talk and/or by activating the immunosuppressive pathway 
of tryptophan catabolism in DCs (see above) (Grohmann 
et al 2002). CTLA4-Ig efﬁ  ciently prevents acute heart or 
kidney rejection in many mouse and rat models (Turka et al 
1992; Glysing-Jensen et al 1997; Sayegh et al 1995, 1997). 
In some animal models, it inhibits the T-cell-dependent 
antibody response and prevents the progression of chronic 
rejection (Azuma et al 1996; Judge et al 1996). However, it 
induces long-lasting tolerance in only a few models of heart 
or kidney transplantation (Lenschow et al 1992; Sayegh et al 
1995; Yamada et al 2001; Ito et al 2005), and not in more 
stringent models, such as mouse skin and islet transplantation 
(Trambley et al 1999; Rothstein et al 2001; Sho et al 2005). 
Transplantation tolerance is used to indicate that a single 
administration of an immunosuppressant at the time of trans-
plantation is sufﬁ  cient to ensure an indeﬁ  nite donor-speciﬁ  c 
graft survival. The inability of CTLA4-Ig to generate such 
tolerance may be the consequence of various factors:
1.  Costimulation blockade is less effective in memory T-cells 
and effector CD8+ T-cells than in naïve T-cells (Onodera 
et al 1997; Trambley et al 1999; Valujskikh et al 2002).
2.  CTLA4 plays a key role in downregulating T-cell 
responses, independently of CD28/B7 blockade. CTLA-4 
signaling is essential for initial engraftment (Judge et al 
1999; Sho et al 2002). Moreover, in the absence of 
CD28-mediated costimulation (CD28-deﬁ  cient animals), 
interaction of CTLA-4 with B7 results in down-regulation 
of alloimmune response and prolongation of allograft 
survival. The blockade of CTLA-4/B7 interactions with 
CTLA-4-Ig or blocking anti-CTLA-4 antibodies abol-
ishes the prolongation allograft survival observed in these 
animals (Yamada et al 2001).
3.  Suppression of the alloimmune response requires a func-
tional CTLA-4/B7 pathway between T-reg and effector 
cells (see above) (Kingsley et al 2002; Paust et al 2004).
The CD40/CD40L pathway
Similar to CD28/B7, the blockade of the CD40/CD40L 
pathway with an anti-CD40L mAb rarely results in durable 
tolerance when used alone (Parker et al 1995; Hancock et al 
1996; Larsen et al 1996, 2005). The effects of anti-CD40L 
mAb are reversible, so prolonged administration is often 
required (Kirk et al 1999). However, simultaneous CD40/
CD40L and B7/CD28 blockade may promote indeﬁ  nite 
graft survival, even in stringent models such as mouse skin 
transplantation and xenotransplantation (Larsen et al 1996; 
Elwood et al 1998; Li et al 1999).
Costimulation blockade in non-human 
primates
Non-human primate (NHP) models must be used to make the 
jump from small animal models to clinical protocols. In ado-
lescent rhesus monkeys, kidney graft survival increases from 
8 days to 30 days when CTLA4-Ig is used alone and to up to 
six months if CTLA4-Ig plus humanized anti-CD40L antibody 
(hu-anti-CD40L) are used (Kirk et al 1997). Survival was 
similar with hu-anti-CD40L antibody alone, suggesting that 
CD40/CD40L pathway blockade is critical (Elster et al 2001). 
Treatment did not prevent chronic rejection as routine biopsies 
on day 28 showed, in all animals, donor-speciﬁ  c antibodies 
and focal perivascular inﬁ  ltrate (Kirk et al 1999).
Delivery of the ﬁ  rst signal without costimulation signal 
drives T-cells to a state of anergy (Schwartz 1990; Lom-
bardi et al 1994). New protocols, based upon the suppressor 
properties of these anergic T-cells, can improve the results 
of costimulation blockade in NHPs. In human bone mar-
row transplantation, the treatment of donor bone marrow 
ex vivo with CTLA4-Ig and its coculture with irradiated Biologics: Targets & Therapy 2007:1(3) 209
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recipient-cells to induce donor-speciﬁ  c anergic T-cells before 
its re-injection to the recipient resulted in a low risk of graft-
versus-host-disease (Guinan et al 1999). Similarly, in NHP 
models, when recipient splenic T-cells are cocultured with 
irradiated donor splenocytes in the presence of both anti-
human CD80 and CD86 mAbs and re-injected into recipient, 
graft survival was indeﬁ  nite in 50% of cases (Bashuda et al 
2005). The simplicity, safety and efﬁ  cacy of this protocol 
make it suitable for application to human transplantation.
Development of LEA29Y 
(belatacept) and ﬁ  rst clinical 
trial in renal transplantation
It can be difﬁ  cult to transpose experimental ﬁ  ndings in NHPs 
to human clinical trials, because primates lack “heterologous 
immunity”. Indeed, the animals used are raised in captivity 
and have limited exposure to non-self antigens; consequently 
they may not have an extensive repertoire of effector/memory 
cells (Elster et al 2004).
Preliminary clinical results with CD40 
pathway targeting
The ﬁ  rst agent used to block costimulation in human trials 
was huC58, a humanized anti-CD40L antibody. This agent 
was well tolerated in NHPs but its development for human 
use was discontinued after seven patients suffered unantici-
pated thromboembolic events (Kawai et al 2000). This com-
plication reﬂ  ects the importance of costimulatory molecule 
expression by non-lymphoid cells. Indeed, CD40L has been 
detected on the surface of activated platelets and has been 
shown to activate endothelium. Moreover, the absence of 
CD40L affects the stability of arterial thrombi and delays 
arterial occlusion in vivo, in a CD40-independent manner 
(Andre et al 2002). This antibody was not able to prevent 
acute rejection in 5 of 7 seven kidney transplant patients in 
a phase I trial (Vincenti 2002). Thus, targeting CD40 rather 
than its ligand was considered as an alternative, so as to avoid 
these thromboembolic complications. A chimeric anti-human 
CD40 antibody, Chi220, has recently been developed to 
circumvent these adverse events. It has proved particularly 
effective in combination with CTLA4-Ig for islet transplan-
tation in NHPs, with the property of transiently depleting B 
cells (Adams et al 2005).
Development of LEA29Y
Similar to the CD40/CD40L pathway, the two components 
of the B7/CD28 pair have been targeted with biological 
immunosuppressive agents. h1F1 and h3D1 are two 
humanized antibodies directed against CD80 and CD86, 
respectively, which have been shown to inhibit CD28-
dependent T-cell proliferation in vitro. In vivo, provided that 
both mAbs are used together, they prolong kidney allograft 
survival in NHPs (Hausen et al 2001). At phase I clinical 
trial stage, in combination with steroids, cyclosporine and 
mycophenolate mofetil, they proved to be safe and effective. 
However, they were subsequently withdrawn from further 
development, despite the good safety proﬁ  le, for ﬁ  nancial 
reasons (Vincenti 2002).
CTLA4-Ig (abatacept) is a fusion protein consisting of the 
extracellular domain of CTLA-4 and the Fc domain of IgG. 
The afﬁ  nity of CTLA4-Ig for CD80 is 200 times higher 
than that for CD86 and it is 100 times more potent for the 
blockade of CD80-dependent costimulation than for that of 
CD86-dependent costimulation (Linsley et al 1994). Insuf-
ﬁ  cient blockade of CD28/B7 interaction may partly account 
for the limited results obtained in NHP models. However, 
treatment with CTLA4-Ig is associated with a signiﬁ  cant 
clinical improvement of T-cell-mediated autoimmune condi-
tions, including psoriasis and rheumatoid arthritis (Abrams 
et al 1999; Kremer et al 2003).
A mutagenesis and screening strategy using various 
CTLA4-Ig variants has been used to identify high-avidity 
mutants with slower dissociation rates (Larsen et al 2005). 
Two amino-acid substitutions in the binding domain (L104E 
and A29Y) were identiﬁ  ed as potentially useful, leading to the 
development of a new molecule, LEA29Y or belatacept. Its 
binding avidity to CD80 and CD86 was twofold and fourfold 
higher, respectively, and inhibition of T-cell activation was 
tenfold more powerful than those of CTLA4-Ig. NHPs studies 
showed a prolongation of kidney allograft survival and an 
inhibition of anti-donor humoral response when belatacept 
was used alone or in combination with steroids and MMF 
(Larsen et al 2005).
First clinical trial with belatacept in renal 
transplantation
A large-scale 12-month study has been conducted to assess 
the efﬁ  cacy of a strategy based upon costimulation blockade 
with belatacept in renal transplantation (Vincenti et al 2005). 
This phase 2 multicenter study included 218 adult kidney 
recipients at low immunological risk, randomly assigned to 
receive an intensive regimen of belatacept, a less-intensive 
regimen, or cyclosporine A (CsA). Belatacept was admin-
istered as peripheral intravenous injections each lasting Biologics: Targets & Therapy 2007:1(3) 210
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30 minutes. Both belatacept regimens included an early phase 
of 10 mg/kg body weight injections every two weeks, and 
a late phase of 5 mg/kg injections (at four-week or eight-
week intervals). For the intensive regimen, the early phase 
involved 11 injections over 6 months and the less intense 
regimen involved 5 injections over 3 months. Patients of all 
three groups also received basiliximab induction therapy, 
mycophenolate mofetil and steroids.
The primary non-inferiority objective was reached, with 
the following incidences of acute rejection at six months: 6% 
(less-intensive belatacept), 7% (intensive belatacept) and 8% 
(CsA). Subclinical rejection at month-12 routine biopsy was 
more common with less-intensive belatacept (20 %) than 
with intensive belatacept (9 %) or cyclosporine (11%). The 
glomerular ﬁ  ltration rate measured with iohexol clearance 
at 12 months was signiﬁ  cantly higher in patients receiving 
belatacept than in those treated with CsA (66.3 and 62.1 
versus 53.5 ml/min/1.73 m2). By month 12, the incidence 
of chronic allograft nephropathy as assessed from protocol 
biopsy was lower in patients receiving belatacept: 29% (less 
intensive) and 20% (intensive) versus 44% in the cyclospo-
rine arm. Four patients in the cyclosporine arm died (two 
from cardiovascular disease) and one in the less intensive 
belatacept arm (from infection).
The side effects were also noted for the three groups. The 
frequency of infections was similar (around 75%) in all three 
groups. Cancers occurred in two patients treated with intensive 
belatacept (one breast cancer, and one post-transplantation 
lymphoproliferative disorder (PTLD)) and in two patients 
treated with CsA (one skin cancer, and one thyroid cancer). 
However, PTLD developed in two further patients treated with 
the intensive regimen 2 and 13 months after the replacement 
of belatacept with tacrolimus at the end of study. All cases 
of PTLD were associated with primary Epstein-Barr virus 
infection or treatment with muromonab-CD3, both of which 
are known risk factors for the disorder. Approximately half the 
patients enrolled voluntarily in a long-term extension of the 
protocol after one year of treatment and no additional case of 
PTLD occurred after up to four years of follow-up. For meta-
bolic cardiovascular and markers, total, LDL and HDL cho-
lesterol levels were similar in the three groups but signiﬁ  cantly 
more patients in the cyclosporine arm were receiving lipid-
lowering drugs. Similarly, the percentage of patients treated 
for hypertension was higher under cyclosporine than under 
belatacept (92% versus 88 and 83%). The incidence of post-
transplantation diabetes mellitus was 8% under cyclosporine 
and 1% in each belatacept group. The rate of discontinuation 
was similar in the three groups (22%, 25% and 27%).
In summary, belatacept belongs to a new class of 
immunosuppressants and is the ﬁ  rst maintenance drug to 
have an immune speciﬁ  city. Contrary to many biological 
agents used for induction or treatment of acute rejection 
(murumonab, thymoglobulin), belatacept does not appear to 
act by depleting T-cells or to affect number and function of 
regulatory T-cells (Moreland et al 2002; Hirose et al 2004; 
Chavez et al 2007). Although its long-term safety remains to 
be conﬁ  rmed, its administration is well tolerated and seems 
to protect patients against adverse renal, cardiovascular and 
metabolic effects encountered with calcineurin inhibitors, 
whilst providing equally effective immunosuppression.
Furthermore, this totally calcineurin inhibitor-free regimen 
is the ﬁ  rst to be associated with a very low risk of acute rejec-
tion. The more disappointing aspect is the need to combine 
belatacept with standard immunosuppressants (basiliximab, 
steroids and mycophenolate mofetil). This may explain the 
similar rates of infection in the three groups and possibly 
the unanticipated incidence of PTLD in the belatacept arm. 
Indeed, the absence of infectious and neoplasic complica-
tions observed in rheumatoid arthritis with abatacept and 
belatacept (in studies against placebo) suggests that the side 
effects reported in renal transplant patients are due to drugs 
associated with belatacept (Moreland et al 2002).
Targeting novel costimulatory 
pathways
It is now apparent that T-cell activation and transplant 
rejection may proceed in the absence of CD28/B7 and 
CD40/CD40L signaling. Memory T-cells (London et al 
2000; Valujskikh et al 2002) and CD8+ effector T-cells 
(Ensminger et al 2000), which play a major role in rejec-
tion, are less susceptible to this classical costimulatory 
blockade. Several other members of the CD28/B7 and 
TNF/TNF-Receptor (TNF-R) superfamilies deliver posi-
tive or negative costimulatory signals, early or late after 
encountering antigen (Table 3). These signals are not lim-
ited to T-cell/APC interactions, but also involve interplay 
between T-cells and other T-cells, B-cells or parenchymal 
cells. Several of these molecules have been targeted in 
animal models of transplantation.
In the B7/CD28 superfamily, the Induced Costimula-
tory Molecule (ICOS) and Programmed Death-1 (PD-1) 
share homology with CD28. However, unlike CD28 these 
two molecules are not expressed on naïve T-cells but are 
induced on T-cells after activation. Thus, ICOS signal-
ing is required for the activation and function of effector 
and memory T-cells, whereas CD28 primes naïve T-cells Biologics: Targets & Therapy 2007:1(3) 211
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(Coyle et al 2000). PD-1 expression is not restricted to 
T-cells like other members of the CD28 family (Green-
wald et al 2005). Its two ligands, PD-L1 (B7-H1) and PD-
L2 (B7-DC) are also constitutively expressed on a large 
panel of non-lymphoid organs, suggesting a peripheral 
regulation of self-reactive T- or B-cells. PD-1 ligation 
transmits a potent inhibitory signal in the early stages of 
T-cell activation. B7-H3 is a B7 homolog inducible in 
APCs, which binds a putative receptor on T-cells, result-
ing in increased T-cell proliferation.
Simplistically, TNF-R-family members are expressed by 
T-cells and their ligands are expressed by APCs (Table 3) (Croft 
2003). TNF-R/TNF interactions are critical for the clonal expan-
sion/effector phases of immune responses, and involve DC/T-cell 
and B/T-cell interactions. TNF-Rs may be either constitutively 
expressed by naïve T-cells, as is the case for CD27, or induced 
after antigen recognition, as are OX40, 4-1BB, and CD27. 
Their ligands OX40L, 4-1BBL, and CD70 are not constitutively 
expressed by APCs but are induced simultaneously with their 
receptors on T-cells, one to several days after activation (Croft 
2003). Despite variability in expression, binding to TNF-Rs 
increases cytokine secretion and the proliferation of T-cells 
receiving the TCR signal (Croft 2003).
The pair of costimulatory molecules B- and T-lympocyte 
attenuator (BTLA)/herpervirus-entry mediator (HVEM) 
is unique in the fact that their interaction bridges the two 
superfamilies of receptors, CD28 for BTLA and TNF-R for 
HVEM. This crosstalk is unusual because BTLA is known 
to inhibit T-cell responses whereas HVEM is an activator 
receptor (Murphy et al 2006). Their widespread expression 
(Table 3) suggests a regulatory role for many cell types. Few 
and contradictory data are available about the role of BTLA 
in allogeneic response. Tao et al have shown that targeting of 
BTLA with a blocking antibody prompted rapid rejection of 
partially MHC-mismatched murine heart allografts whereas 
it prolonged survival of fully MHC-mismatched allografts 
(Tao et al 2005). The role of BTLA and its ligand has to be 
precised by further experimental models.
The use of single agents blocking costimulation has proved 
to be insufﬁ  cient in stringent models of transplantation. In 
particular, the results obtained with LEA29Y in NHP models 
of kidney transplantation led investigators to combine it with 
conventional immunosuppressive reagents for clinical applica-
tions so as to minimize the risk of acute rejection (Larsen et al 
2005; Vincenti et al 2005). Given the diversity, redundancy 
and complementary nature of all the various costimulation 
molecules described above, strategies for human transplanta-
tion in the future may involve the simultaneous blockade of 
several selected pathways or the concomitant use of currently 
approved conventional immunosuppressants.
Future directions for costimulation 
blockade
In conclusion, a short course of a costimulation-blocking 
agent to achieve drug-free antigen-speciﬁ  c tolerance in 
transplantation patients does not appear to be a realistic goal 
in the immediate future. However, costimulation blockade 
with belatacept has proved to be a powerful alternative to 
calcineurin inhibitors, and the non-immune side effects and 
consequences on graft and patient survival can therefore be 
avoided. This molecule is currently being evaluated in phase 
III trials versus cyclosporine in recipients of extended-criteria 
donor kidneys.
Nevertheless, there are issues that require careful con-
sideration at this stage of development:
1.  The short half-life of classical oral immunosuppressive 
drugs implies a relative reversibility of their effects, and 
this is a major point in cases of malignant or infectious 
complications. Future trials need to determine whether the 
long half-life of biological agents precludes their safety. 
In the belatacept trial, the three PTLD affecting patients 
receiving belatacept were not expected, and indicate that 
this new agent does not provide speciﬁ  c immunosup-
pression and may block immune surveillance of tumors. 
These patients should be carefully followed-up because 
the long-term safety of belatacept is not known.
2.  More practically, although some patients are happy to take 
fewer tablets each day, the intravenous route of administra-
tion makes the ambulatory follow-up of transplant patients 
more complicated. The development of subcutaneous deliv-
ery systems is an essential step if the use of these agents 
is to become more generalized. In our experience, patients 
found intravenous administration of belatacept every one 
or two months acceptable, because they have to come to 
the hospital for medical visits anyway, and this meant that 
they had fewer tablets to take. Indeed, the list of drugs that 
a transplant patient has to take to treat the side-effects of 
immunosuppressive molecules is long and may result in 
non-adherence with treatment; this is an established risk 
factor for late allograft failure. (Humar et al 1999)
3.  The best use of costimulation blocking agents in the long 
term needs to be determined, and it is not known such 
long-term use has an effect, positive or negative, on the 
process of accommodation, in other words whether it is 
possible to give lower doses over time as is the case for 
drugs currently in use.Biologics: Targets & Therapy 2007:1(3) 212
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4.  Monitoring tools adapted to these costimulation blocking 
agents are required, as with other immunosuppressants. For 
example, monitoring of belatacept concentrations in blood is 
possible and studies are necessary to ﬁ  nd out whether there 
is a correlation with the incidence of acute rejection.
It is clear that single therapy cannot currently be 
used, probably because of the redundancy of the various 
costimulation pathways. Consequently, costimulation 
blocking agents are actually envisioned as components 
of combination therapy. The need to use additional drugs 
may be responsible for a rate of infectious and neoplasic 
complications that is similar to that observed in classical 
protocols. Consequently, combined targeting of several 
costimulation pathways of both B7/CD28 and TNF/TNF-R 
families could result in a reinforced immunosuppression 
whilst retaining a degree of immune speciﬁ  city. Experi-
mental transplantation models using agonists or blocking 
reagents have already been used to investigate most of these 
pathways, and several appear to be attractive targets for 
future clinical applications. Further studies are necessary 
to determine how important these new pathways are in the 
human alloimmune response.
References
Abrams JR, Lebwohl MG, Guzzo CA, et al. 1999. CTLA4Ig-mediated 
blockade of T-cell costimulation in patients with psoriasis vulgaris. 
J Clin Invest, 103:1243–52.
Adams AB, Shirasugi N, Jones TR, et al. 2005. Development of a chime-
ric anti-CD40 monoclonal antibody that synergizes with LEA29Y to 
prolong islet allograft survival. J Immunol, 174:542–50.
Andre P, Prasad KS, Denis CV, et al. 2002. CD40L stabilizes arterial thrombi 
by a beta3 integrin–dependent mechanism. Nat Med, 8:247–52.
Azuma H, Chandraker A, Nadeau K, et al. 1996. Blockade of T-cell costimu-
lation prevents development of experimental chronic renal allograft 
rejection. Proc Natl Acad Sci USA, 93:12439–44.
Bashuda H, Kimikawa M, Seino K, et al. 2005. Renal allograft rejection is 
prevented by adoptive transfer of anergic T-cells in nonhuman primates. 
J Clin Invest, 115:1896–902.
Bromley SK, Iaboni A, Davis SJ, et al. 2001. The immunological synapse 
and CD28-CD80 interactions. Nat Immunol, 2:1159–66.
Chavez H, Beaudreuil S, Abbed K, et al. 2007. Absence of CD4-CD25 
regulatory T-cell expansion in renal transplanted patients treated in 
vivo with belatacept mediated CD28-CD80/86 blockade. Transpl 
Immunol, 17:243–8.
Cohen DJ, St Martin L, Christensen LL, et al. 2006. Kidney and pancreas 
transplantation in the United States, 1995-2004. Am J Transplant, 
6:1153–69.
Coyle AJ, Lehar S, Lloyd C, et al. 2000. The CD28-related molecule 
ICOS is required for effective T-cell-dependent immune responses. 
Immunity, 13:95–105.
Croft M. 2003. Co-stimulatory members of the TNFR family: keys to effec-
tive t-cell immunity? Nat Rev Immunol, 3:609–20.
Denton MD, Magee CC, Sayegh MH. 1999. Immunosuppressive strategies 
in transplantation. Lancet, 353:1083–91.
Ekberg H, Grinyo J, Nashan B, et al. 2007. Cyclosporine sparing with myco-
phenolate mofetil, daclizumab and corticosteroids in renal allograft 
recipients: the CAESAR Study. Am J Transplant, 7:560–70.
Elster EA, Xu H, Tadaki DK, et al. 2001. Treatment with the humanized 
CD154-speciﬁ  c monoclonal antibody, hu5C8, prevents acute rejection 
of primary skin allografts in nonhuman primates. Transplantation, 
72:1473–8.
Elster EA, Hale DA, Mannon RB, et al. 2004. The road to tolerance: renal 
transplant tolerance induction in nonhuman primate studies and clinical 
trials. Transpl Immunol, 13:87–99.
Elwood ET, Larsen CP, Cho HR, et al. 1998. Prolonged acceptance of 
concordant and discordant xenografts with combined CD40 and CD28 
pathway blockade. Transplantation, 65:1422–8.
Ensminger SM, Witzke O, Spriewald BM, et al. 2000. CD8+ T-cells con-
tribute to the development of transplant arteriosclerosis despite CD154 
blockade. Transplantation, 69:2609–12.
Finger EB, Bluestone JA. 2002. When ligand becomes receptor–tolerance 
via B7 signaling on DCs. Nat Immunol, 3:1056–7.
Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh MH, et al. 1997. Chronic 
blockade of CD28-B7-mediated T-cell costimulation by CTLA-4-Ig 
reduces intimal thickening in MHC class I and II incompatible mouse 
heart allografts. Transplantation, 64:1641–5.
Graca L, Thompson S, Lin CY, et al. 2002. Both CD4(+)CD25(+) and 
CD4(+)CD25(−) regulatory cells mediate dominant transplantation 
tolerance. J Immunol, 168:5558–65.
Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. 
Annu Rev Immunol, 23:515–48.
Grohmann U, Orabona C, Fallarino F, et al. 2002. CTLA-4-Ig regulates 
tryptophan catabolism in vivo. Nat Immunol, 3:1097–101.
Guinan EC, Boussiotis VA, Neuberg D, et al. 1999. Transplantation of 
anergic histoincompatible bone marrow allografts. N Engl J Med, 
340:1704–14.
Halloran PF. 2004. Immunosuppressive drugs for kidney transplantation. 
N Engl J Med, 351:2715–29.
Hancock WW, Sayegh MH, Zheng XG, et al. 1996. Costimulatory function 
and expression of CD40 ligand, CD80, and CD86 in vascularized murine 
cardiac allograft rejection. Proc Natl Acad Sci USA, 93:13967–72.
Hariharan S, Johnson CP, Bresnahan BA, et al. 2000. Improved graft 
survival after renal transplantation in the United States, 1988 to 1996. 
N Engl J Med, 342:605–12.
Hausen B, Klupp J, Christians U, et al. 2001. Coadministration of either 
cyclosporine or steroids with humanized monoclonal antibodies against 
CD80 and CD86 successfully prolong allograft survival after life sup-
porting renal transplantation in cynomolgus monkeys. Transplantation, 
72:1128–37.
Hirose K, Posselt AM, Stock PG, et al. 2004. Treatment of kidney transplant 
patients with the novel co-stimulatory blocker LEA29Y and anti-IL2 
receptor does not impede the development of regulatory T-cells. Am J 
Transplant, 4(Suppl 8):442.
Humar A, Kerr S, Gillingham KJ, et al. 1999. Features of acute rejection that 
increase risk for chronic rejection. Transplantation, 68:1200–3.
Ito T, Ueno T, Clarkson MR, et al. 2005. Analysis of the role of negative 
T- cell costimulatory pathways in CD4 and CD8 T-cell-mediated allo-
immune responses in vivo. J Immunol, 174:6648–56.
Judge TA, Tang A, Turka LA. 1996. Immunosuppression through block-
ade of CD28:B7-mediated costimulatory signals. Immunol Res, 
15:38–49.
Judge TA, Wu Z, Zheng X-G, et al. 1999. The Role of CD80, CD86, and 
CTLA-4 in alloimmune responses and the induction of long-term 
allograft survival. J Immunol, 162:1947–51.
Kaplan B, Budde K. 2007. Lessons from the CAESAR Study: calcineurin 
inhibitors–can’t live with them and can’t live without them. Am J 
Transplant, 7:495–6.
Kauffman HM, Cherikh WS, Cheng Y, et al. 2005. Maintenance immu-
nosuppression with target-of-rapamycin inhibitors is associated 
with a reduced incidence of de novo malignancies. Transplantation, 
80:883–9.
Kawai T, Andrews D, Colvin RB, et al. 2000. Thromboembolic complica-
tions after treatment with monoclonal antibody against CD40 ligand. 
Nat Med, 6:114.Biologics: Targets & Therapy 2007:1(3) 213
Costimulation blockade with belatacept
Kingsley CI, Karim M, Bushell AR, et al. 2002. CD25+CD4+ regulatory 
T-cells prevent graft rejection: CTLA-4- and IL-10-dependent immu-
noregulation of alloresponses. J Immunol, 168:1080–6.
Kirk AD, Burkly LC, Batty DS, et al. 1999. Treatment with humanized 
monoclonal antibody against CD154 prevents acute renal allograft 
rejection in nonhuman primates. Nat Med, 5:686–93.
Kirk AD, Harlan DM, Armstrong NN, et al. 1997. CTLA-4-Ig and anti-
CD40 ligand prevent renal allograft rejection in primates. Proc Natl 
Acad Sci USA, 94:8789–94.
Kremer JM, Westhovens R, Leon M, et al. 2003. Treatment of rheumatoid 
arthritis by selective inhibition of T-cell activation with fusion protein 
CTLA-4-Ig. N Engl J Med, 349:1907–15.
Larsen CP, Elwood ET, Alexander DZ, et al. 1996. Long-term acceptance 
of skin and cardiac allografts after blocking CD40 and CD28 pathways. 
Nature, 381:434–8.
Larsen CP, Pearson TC, Adams AB, et al. 2005. Rational development of 
LEA29Y (belatacept), a high-afﬁ  nity variant of CTLA-4-Ig with potent 
immunosuppressive properties. Am J Transplant, 5:443–53.
Lee PC, Terasaki PI, Takemoto SK, et al. 2002. All chronic rejection fail-
ures of kidney transplants were preceded by the development of HLA 
antibodies. Transplantation, 74:1192–4.
Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. 1992. Long-term survival 
of xenogeneic pancreatic islet grafts induced by CTLA-4-lg. Science, 
257:789–92.
Li Y, Li XC, Zheng XX, et al. 1999. Blocking both signal 1 and signal 2 of 
T-cell activation prevents apoptosis of alloreactive T-cells and induction 
of peripheral allograft tolerance. Nat Med, 5:1298–302.
Linsley PS, Greene JL, Brady W, et al. 1994. Human B7-1 (CD80) and 
B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 
and CTLA-4 receptors. Immunity, 1:793–801.
Lombardi G, Sidhu S, Batchelor R, et al. 1994. Anergic T-cells as suppressor 
cells in vitro. Science, 264:1587–9.
London CA, Lodge MP, Abbas AK. 2000. Functional responses and 
costimulator dependence of memory CD4+ T-cells. J Immunol, 
164:265–72.
Meier-Kriesche HU, Schold JD, Kaplan B. 2004. Long-term renal allograft 
survival: have we made signiﬁ  cant progress or is it time to rethink our 
analytic and therapeutic strategies? Am J Transplant, 4:1289–95.
Moreland LW, Alten R, Van den, Bosch F, et al. 2002. Costimulatory 
blockade in patients with rheumatoid arthritis: a pilot, dose-ﬁ  nding, 
double-blind, placebo-controlled clinical trial evaluating CTLA-4-Ig 
and LEA29Y eighty-ﬁ  ve days after the ﬁ  rst infusion. Arthritis Rheum, 
46:1470–9.
Murphy KM, Nelson CA, Sedy JR. 2006. Balancing co-stimulation and 
inhibition with BTLA and HVEM. Nat Rev Immunol, 6:671–81.
Muthukumar T, Dadhania D, Ding R, et al. 2005. Messenger RNA for 
FOXP3 in the urine of renal-allograft recipients. N Engl J Med, 
353:2342–51.
Nankivell BJ, Borrows RJ, Fung CL, et al. 2003. The natural history of 
chronic allograft nephropathy. N Engl J Med, 349:2326–33.
Onodera K, Chandraker A, Schaub M, et al. 1997. CD28-B7 T-cell costimu-
latory blockade by CTLA-4-Ig in sensitized rat recipients: induction of 
transplantation tolerance in association with depressed cell-mediated 
and humoral immune responses. J Immunol, 159:1711–17.
Parker DC, Greiner DL, Phillips NE, et al. 1995. Survival of mouse 
pancreatic islet allografts in recipients treated with allogeneic small 
lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA, 
92:9560–4.
Pascual M, Theruvath T, Kawai T, et al. 2002. Strategies to improve 
long-term outcomes after renal transplantation. N Engl J Med, 
346:580–90.
Paust S, Lu L, McCarty N, et al. 2004. Engagement of B7 on effector T-cells 
by regulatory T-cells prevents autoimmune disease. Proc Natl Acad Sci 
USA, 101:10398–403.
Pree I, Bigenzahn S, Fuchs D, et al. 2007. CTLA4Ig promotes the induction 
of hematopoietic chimerism and tolerance independently of Indole-
amine-2,3-dioxygenase. Transplantation, 83:663–7.
Rosengard BR, Feng S, Alfrey EJ, et al. 2002. Report of the Crystal City 
meeting to maximize the use of organs recovered from the cadaver 
donor. Am J Transplant, 2:701–11.
Rothstein DM, Livak MF, Kishimoto K, et al. 2001. Targeting signal 1 
through CD45RB synergizes with CD40 ligand blockade and promotes 
long term engraftment and tolerance in stringent transplant models. 
J Immunol, 166:322–9.
Sayegh MH, Akalin E, Hancock WW, et al. 1995. CD28-B7 blockade after 
alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. 
J Exp Med, 181:1869–74.
Sayegh MH, Zheng XG, Magee C, et al. 1997. Donor antigen is necessary 
for the prevention of chronic rejection in CTLA4Ig-treated murine 
cardiac allograft recipients. Transplantation, 64:1646–50.
Schwartz RH. 1990. A cell culture model for T-lymphocyte clonal anergy. 
Science, 248:1349–56.
Sho M, Kishimoto K, Harada H, et al. 2005. Requirements for induction 
and maintenance of peripheral tolerance in stringent allograft models. 
Proc Natl Acad Sci USA, 102:13230–5.
Sho M, Yamada A, Najaﬁ  an N, et al. 2002. Physiological mechanisms of 
regulating alloimmunity: cytokines CTLA-4, CD25+ Cells, and the 
alloreactive T-cell clone size. J Immunol, 169:3744–51.
Snanoudj R, Beaudreuil S, Arzouk N, et al. 2005. Immunological strategies 
targeting B cells in organ grafting. Transplantation, 79:S33–6.
Tao R, Wang L, Han R, et al. 2005. Differential effects of B and 
T-lymphocyte attenuator and programmed death-1 on acceptance of 
partially versus fully MHC-mismatched cardiac allografts. J Immunol, 
175:5774–82.
Terasaki PI, Ozawa M. 2004. Predicting kidney graft failure by HLA anti-
bodies: a prospective trial. Am J Transplant, 4:438–43.
Trambley J, Bingaman AW, Lin A, et al. 1999. Asialo GM1(+) CD8(+) 
T-cells play a critical role in costimulation blockade-resistant allograft 
rejection. J Clin Invest, 104:1715–22.
Turka LA, Linsley PS, Lin H, et al. 1992. T-cell activation by the CD28 
ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl 
Acad Sci USA, 89:11102–5.
Valujskikh A, Pantenburg B, Heeger PS. 2002. Primed allospeciﬁ  c T-cells 
prevent the effects of costimulatory blockade on prolonged cardiac 
allograft survival in mice. Am J Transplant, 2:501–9.
van Kooten C, Banchereau J. 1997. Functions of CD40 on B cells, dendritic 
cells and other cells. Curr Opin Immunol, 9:330–7.
Vincenti F. 2002. What’s in the pipeline? New immunosuppressive drugs 
in transplantation. Am J Transplant, 2:898–903.
Vincenti F, Larsen C, Durrbach A, et al. 2005. Costimulation blockade with 
belatacept in renal transplantation. N Engl J Med, 353:770–81.
von Andrian UH, Mackay CR. 2000. T-cell function and migration. Two 
sides of the same coin. N Engl J Med, 343:1020–34.
von Boehmer H. 2005. Mechanisms of suppression by suppressor T-cells. 
Nat Immunol, 6:338–44.
West M, Sutherland DE, Matas AJ. 1996. Kidney transplant recipients who 
die with functioning grafts: serum creatinine level and cause of death. 
Transplantation, 62:1029–30.
Yamada A, Kishimoto K, Dong VM, et al. 2001. CD28-independent costimu-
lation of T-cells in alloimmune responses. J Immunol, 167:140–6.